Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer

Stomach Neoplasms Clinical Trial

Official title:

Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02289547
• Other study ID #: CMCGA1 Trial
• Status: Recruiting
• Phase: Phase 3
• First received: October 30, 2014
• Last updated: June 13, 2017
• Start date: May 2015
• Est. completion date: January 2019

Study information

• Verified date: June 2017
• Source: The Catholic University of Korea
• Contact: Byoungyong Shim, M.D., Ph.D
• Phone: 82312497126
• Email: shimby[@]catholic.ac.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

XELOX regimen had a more favorable toxicity profile compared to cisplatin for patients with advanced gastric cancer. The safety profile of oxaliplatin makes it an ideal candidate for combination therapy. However, oxaliplatin induce sensory neuropathy, a cumulative, dose-related toxicity. It may therefore be possible to devise capecitabine maintenance regimen which achieves maximum treatment effect before cumulative neurotoxicity appears. We study that randomized Phase III study of Xelox (Capecitabine plus Oxaliplatin) followed by maintenance Capecitabine or Observation in the gastric cancer patients of stable disease after 6 cycle 1st line of XELOX chemotherapy .

Description:

Study rationale : Park et al. observed the oxaliplatin as part of XELOX regimen had a more favorable toxicity profile compared to cisplatin for patients with advanced gastric cancer. The safety profile of oxaliplatin makes it an ideal candidate for combination therapy. However, oxaliplatin induce sensory neuropathy, a cumulative, dose-related toxicity. The response with XELOX regimen generally occurs earlier. It may therefore be possible to devise capecitabine maintenance regimen which achieves maximum treatment effect before cumulative neurotoxicity appears. This regimen was studied in colon and breast cancer.

• Objective: Primary: To evaluate progression free survival Secondary: To evaluated overall survival, response rate, toxicity profile of chemotherapy, quality of life

• Design :Multicenter randomized controlled phase III open label trial Study subjects will be randomized to two groups in a ratio of 1:1 Subjects More than stable disease after 6 cycle 1st line of XELOX chemotherapy (OR non-complete response/non-progressive disease in cases of non-measurable disease before XELOX chemotherapy),

• Treatment Groups Group A : Capecitabine: Capecitabine 1000mg/m2 bid D1-14, q 3 week Group B : Observation

• Evaluation of response and toxicity A response will be evaluated radiologically every two cycles thereafter, or when progression is suspicious by RECIST criteria version 1.1.

A progression-free survival is defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause.

An overall survival is defined as the time from the 1stdate of chemotherapy to the date of death.

Safety will be evaluated every treatment by NCI-CTCAE version 4.0.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 184
• Est. completion date: January 2019
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven gastric cancer

• Minimum age of 18 years

• Stage IV (regardless of the presence or absence of measurable disease by RECIST criteria) or recurrent after curative surgery

• Negative expression (0, 1) of Her2 Immuno-histochemistry or negative amplification of FISH in Her2 Immuno-histochemistry 2+

• More than stable disease after 6 cycle 1st line of XELOX chemotherapy (OR non-Complete response/non-Progressive disease in cases of non-measurable disease before XELOX chemotherapy)

• Eastern Cooperative Oncology Group Performance status 0-2

• Adequate bone marrow function: Absolute neutrophil count = 1,500/ul, Hemoglobin = 8 g/dL, platelet = 100,000/µl

• Adequate renal function: Serum creatinine = 1.5 x ULN (upper normal limit) or creatinine clearance = 60 ml/min

• Adequate hepatic function: serum bilirubin = 2.5 x UNL, AST and ALT = 2.5 x UNL (= 5 x ULN in the presence of liver metastasis)

• Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital

Exclusion Criteria:

• Patients who were exposed previously to any chemotherapy except XELOX for advanced disease

• Patients who received R0 or R1 resection for metastatic or recurrent gastric cancer and without evaluable/measurable disease

• Disease relapsed during or within 4 months after adjuvant therapy

• Patients who had central nervous system and meningeal metastases

• Patients with significant neurologic or psychiatric disorders

• Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding

• Any previous or concurrent malignancy except for adequately treated non-melanoma skin cancer, in situ cancer of uterine cervix, non-muscle invasive bladder cancer or malignancy without evidence of recurrence within 5 years

Related Conditions & MeSH terms

• Stomach Neoplasms

Intervention

Drug:
• Capecitabine
maintenance capecitabine therapy after six cycles of XELOX

Locations

Country	Name	City	State
Korea, Republic of	Buchon St. Mary's Hospital	Buchon
Korea, Republic of	Daejeon St. Mary's Hospital	Daejeon
Korea, Republic of	Incheon St. Mary's Hospital	Incheon
Korea, Republic of	Seoul St. Mary's Hospital	Seoul
Korea, Republic of	St. Mary's Hospital	Seoul
Korea, Republic of	Bundang Seoul National hospital	Sungnam
Korea, Republic of	St. Vincent's Hospital	Suwon	Gyeonggi-do
Korea, Republic of	Ujeongbu St. Mary's Hospital	Ujeongbu

Sponsors (1)

Lead Sponsor	Collaborator
The Catholic University of Korea

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (5)

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149. — View Citation

De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005 May 9;92(9):1644-9. — View Citation

Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. doi: 10.1093/annonc/mdn717. Epub 2009 Jan 19. — View Citation

Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9. Epub 2007 May 24. — View Citation

Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, Morris J, Lloyd A, Swindell R, Taylor MB, Saunders MP. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer Chemother Pharmacol. 2011 May;67(5):1111-7. doi: 10.1007/s00280-010-1322-0. Epub 2010 Jul 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	every two cycles (6 weeks) until 18 weeks and then every 4 cycles (12 weeks) until progression	From date of randomization until the date of first documented progression, whichever came first, assessed up to 2 years
Secondary	Overall survival	every two cycles (6 weeks) until 18 weeks and then every 4 cycles (12 weeks) until death	From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 years
Secondary	quality of life in patients measured by QLQ-c30 and STO-22	every two cycles (6 weeks) until 18 weeks and then every 4 cycles (12 weeks) until progression	From date of randomization until the date of first documented progression, whichever came first, assessed up to 2 years
Secondary	Toxicity profile of each patients measured by NCI-CTCAE ver 4.0	every two cycles (6 weeks) until 18 weeks and then every 4 cycles (12 weeks) until progression	From date of randomization until the date of first documented progression, whichever came first, assessed up to 2 years